Skip to content
#protein folding Open access

A designer protein binder of KRAS enables exogenous protein degradation

Nov 2026 · Protein Science · Vol 35 · 0 citations · 51 references
Medicine

Abstract

Abstract Targeted protein degradation has emerged as a powerful strategy for modulating intracellular proteins, particularly those lacking traditional small‐molecule binding pockets. While protein‐based degraders expand this approach to undruggable targets, they typically require intracellular expression in target cells, limiting their utility as exogenous research tools. Here, we engineer the Sso7d‐derived KRASG12D binder R11.1.6 for use as a chemically conjugatable, exogenously deliverable degrader scaffold. We show that a C‐terminal arginine‐to‐cysteine variant can be produced in good yield and purity and conjugated to a von Hippel–Lindau (VHL) E3 ligase ligand, albeit with an approximately 10‐fold reduction in KRASG12D affinity relative to parent R11. To reduce the number of lysines available for potential ubiquitination, we generate two lysine‐reduced variants—a fully lysine‐free variant (R11ΔLys) and a “lysine‐lite” variant retaining only the three lysines implicated in KRAS engagement (R11Lite)—and demonstrate that both retain nanomolar affinity for wild‐type KRAS and KRASG12D. Esterification of R11–VHL with an α‐aryl‐α‐diazoamide reagent enables cellular treatment with the chimeric conjugate and leads to VHL‐ligand‐dependent reduction in pan‐RAS levels in HPAF‐II cells, as shown by competition with excess free VHL ligand. Our results establish R11 variants as tractable protein‐engineering scaffolds for developing chemically conjugated biodegraders and provide design principles for engineering lysine‐reduced binders based on the Sso7d scaffold.

Read PDF

Similar papers

Review Open access Nov 2026

Rewriting protein fate: emerging strategies for targeted protein degradation and associated challenges

Abstract Classical small-molecule drugs have traditionally relied on an occupancy-driven paradigm that requires tight and sustained binding to a well-defined pocket on the target protein. Targeted protein degradation (TPD) approaches have emerged to overcome the limitations of traditional pharmacology to promote the se...

Andrea Bertran-Mostazo, Rosa Barrio · 0 citations
#artificial intelligence Open access Oct 2026

Targeted Protein Degradation: PROTACs, Molecular Glues, and the Future of Drug Discovery

The ability to selectively eliminate pathogenic proteins rather than merely inhibit their activity has redefined contemporary drug discovery, positioning targeted protein degradation (TPD) as one of the most significant advances in chemical biology and precision therapeutics. By harnessing endogenous protein quality-co...

K. Choudhary, Chanchal Sahu, B. Patra et al. · 0 citations
Review Nov 2026

Beyond Inhibition: Emerging Approaches in Ubiquitin–Proteasome‐Mediated Protein Degradation for Precision Targeting

Targeted protein degradation (TPD) represents an emerging paradigm in drug discovery, capable of overcoming the limitations of traditional therapeutic strategies based on protein inhibition. Exploiting the ubiquitin–proteasome system (UPS), TPD allows the selective elimination of pathologically relevant proteins. The m...

M. Aliberti, M. Chini, Giuseppe Bifulco et al. · 0 citations
Review Open access Sep 2026

Peptide-Based Molecular Glues for Targeted Protein Degradation

This review examines the comparative advantages of peptide-based architectures, including reduced molecular weight, access to challenging interfaces, and expansion of the addressable E3 ligase repertoire, against persistent translational barriers in proteolytic stability, membrane permeability, immunogenicity, and manu...

Walaa S. Aburayan, Ibrahim A. Alradwan, Beshair A. Alsaffar et al. · 0 citations
Review Oct 2026

From Ubiquitination to Proteasome-Directed Recruiting: Emerging Mechanisms and Therapeutic Potential in Targeted Protein Degradation.

Targeted protein degradation has transformed drug discovery by enabling selective elimination of disease-associated proteins. Beyond classical E3 ligase-recruiting degraders, emerging proteasome-directed strategies seek to recruit targets directly to the proteasome, potentially bypassing E3 ligase dependency and ubiqui...

Yao-Li Shi, Jia-Yi Ma, Yu-Tong Tu et al. · 0 citations

Related blog posts

Google DeepMind Blog Sep 30, 2026

Introducing SynthID Bio

Proof of concept for watermarking AI-generated proteins while preserving biological function.

MIT News · Artificial Intelligence Aug 27, 2026

Looking beyond natural sequences

A new machine-learning framework aims to improve the success rate of computational protein design while moving away from results that reproduce sequences found in nature.

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.